Generalized Pustular Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major generalized pustular psoriasis markets reached a value of US$ 18.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 34.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.
The generalized pustular psoriasis market has been comprehensively analyzed in IMARC's new report titled "Generalized Pustular Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Generalized pustular psoriasis (GPP) refers to a rare and severe form of an autoimmune skin disorder characterized by chronic inflammation and rapid skin cell turnover. This disease manifests as widespread, painful, and itchy skin eruptions accompanied by pus-filled blisters known as pustules. These pustules often appear on red and inflamed skin patches, and when they dry, they form scaly lesions, contributing to the classic appearance of psoriasis. The symptoms of GPP can be debilitating and vary from intense itching and burning sensations to fever and fatigue. The condition can also severely affect the patient's overall quality of life and may even lead to life-threatening complications if left untreated. The diagnosis of this illness mainly involves a thorough clinical evaluation, including a physical examination and a review of the patient's medical history. In a few cases, a biopsy of the diseased skin may be performed to confirm the diagnosis and rule out other similar skin conditions.
The increasing prevalence of somatic mutations in the genes, leading to the overactive production of pro-inflammatory cytokines in the body that can trigger the formation of widespread blisters on the skin, is primarily driving the generalized pustular psoriasis market. In addition to this, the inflating utilization of phototherapy, specifically using ultraviolet (UV) light therapy to reduce skin inflammation and accelerate healing, is also creating a positive outlook for the market. Moreover, the rising application of effective medications, such as corticosteroids and retinoids, since they work by targeting and modulating the inflammatory response and controlling the formation of pustules in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the escalating demand for gene therapy, which aims to rectify the malfunctioning genetic material responsible for the condition, thereby offering a potential cure or long-term disease management solution for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative approaches like targeted immune therapies and Janus kinase (JAK) inhibitors that can address the underlying immune dysregulation and cytokine storm associated with the disease to improve treatment outcomes is expected to drive the generalized pustular psoriasis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the generalized pustular psoriasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for generalized pustular psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the generalized pustular psoriasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the generalized pustular psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the generalized pustular psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current generalized pustular psoriasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the generalized pustular psoriasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the generalized pustular psoriasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the generalized pustular psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with generalized pustular psoriasis across the seven major markets?
What is the size of the generalized pustular psoriasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of generalized pustular psoriasis?
What will be the growth rate of patients across the seven major markets?
Generalized Pustular Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for generalized pustular psoriasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the generalized pustular psoriasis market?
What are the key regulatory events related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by status related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by phase related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by route of administration related to the generalized pustular psoriasis market?
The generalized pustular psoriasis market has been comprehensively analyzed in IMARC's new report titled "Generalized Pustular Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Generalized pustular psoriasis (GPP) refers to a rare and severe form of an autoimmune skin disorder characterized by chronic inflammation and rapid skin cell turnover. This disease manifests as widespread, painful, and itchy skin eruptions accompanied by pus-filled blisters known as pustules. These pustules often appear on red and inflamed skin patches, and when they dry, they form scaly lesions, contributing to the classic appearance of psoriasis. The symptoms of GPP can be debilitating and vary from intense itching and burning sensations to fever and fatigue. The condition can also severely affect the patient's overall quality of life and may even lead to life-threatening complications if left untreated. The diagnosis of this illness mainly involves a thorough clinical evaluation, including a physical examination and a review of the patient's medical history. In a few cases, a biopsy of the diseased skin may be performed to confirm the diagnosis and rule out other similar skin conditions.
The increasing prevalence of somatic mutations in the genes, leading to the overactive production of pro-inflammatory cytokines in the body that can trigger the formation of widespread blisters on the skin, is primarily driving the generalized pustular psoriasis market. In addition to this, the inflating utilization of phototherapy, specifically using ultraviolet (UV) light therapy to reduce skin inflammation and accelerate healing, is also creating a positive outlook for the market. Moreover, the rising application of effective medications, such as corticosteroids and retinoids, since they work by targeting and modulating the inflammatory response and controlling the formation of pustules in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the escalating demand for gene therapy, which aims to rectify the malfunctioning genetic material responsible for the condition, thereby offering a potential cure or long-term disease management solution for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative approaches like targeted immune therapies and Janus kinase (JAK) inhibitors that can address the underlying immune dysregulation and cytokine storm associated with the disease to improve treatment outcomes is expected to drive the generalized pustular psoriasis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the generalized pustular psoriasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for generalized pustular psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the generalized pustular psoriasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the generalized pustular psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the generalized pustular psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current generalized pustular psoriasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the generalized pustular psoriasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the generalized pustular psoriasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the generalized pustular psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of generalized pustular psoriasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with generalized pustular psoriasis across the seven major markets?
What is the size of the generalized pustular psoriasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of generalized pustular psoriasis?
What will be the growth rate of patients across the seven major markets?
Generalized Pustular Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for generalized pustular psoriasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the generalized pustular psoriasis market?
What are the key regulatory events related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by status related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by phase related to the generalized pustular psoriasis market?
What is the structure of clinical trial landscape by route of administration related to the generalized pustular psoriasis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GENERALIZED PUSTULAR PSORIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GENERALIZED PUSTULAR PSORIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GENERALIZED PUSTULAR PSORIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GENERALIZED PUSTULAR PSORIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GENERALIZED PUSTULAR PSORIASIS - UNMET NEEDS
10 GENERALIZED PUSTULAR PSORIASIS - KEY ENDPOINTS OF TREATMENT
11 GENERALIZED PUSTULAR PSORIASIS - MARKETED PRODUCTS
11.1 List of Generalized Pustular Psoriasis Marketed Drugs Across the Top 7 Markets
11.1.1 Taltz (Ixekizumab) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Spevigo (Spesolimab-Sbzo)- Boehringer Ingelheim
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GENERALIZED PUSTULAR PSORIASIS - PIPELINE DRUGS
12.1 List of Generalized Pustular Psoriasis Pipeline Drugs Across the Top 7 Markets
12.1.1 Imsidolimab - AnaptysBio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GENERALIZED PUSTULAR PSORIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GENERALIZED PUSTULAR PSORIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GENERALIZED PUSTULAR PSORIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Generalized Pustular Psoriasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Generalized Pustular Psoriasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Generalized Pustular Psoriasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Generalized Pustular Psoriasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Generalized Pustular Psoriasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Generalized Pustular Psoriasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Generalized Pustular Psoriasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Generalized Pustular Psoriasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
16 GENERALIZED PUSTULAR PSORIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GENERALIZED PUSTULAR PSORIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GENERALIZED PUSTULAR PSORIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GENERALIZED PUSTULAR PSORIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GENERALIZED PUSTULAR PSORIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GENERALIZED PUSTULAR PSORIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GENERALIZED PUSTULAR PSORIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GENERALIZED PUSTULAR PSORIASIS - UNMET NEEDS
10 GENERALIZED PUSTULAR PSORIASIS - KEY ENDPOINTS OF TREATMENT
11 GENERALIZED PUSTULAR PSORIASIS - MARKETED PRODUCTS
11.1 List of Generalized Pustular Psoriasis Marketed Drugs Across the Top 7 Markets
11.1.1 Taltz (Ixekizumab) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Spevigo (Spesolimab-Sbzo)- Boehringer Ingelheim
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GENERALIZED PUSTULAR PSORIASIS - PIPELINE DRUGS
12.1 List of Generalized Pustular Psoriasis Pipeline Drugs Across the Top 7 Markets
12.1.1 Imsidolimab - AnaptysBio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GENERALIZED PUSTULAR PSORIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GENERALIZED PUSTULAR PSORIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GENERALIZED PUSTULAR PSORIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Generalized Pustular Psoriasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Generalized Pustular Psoriasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Generalized Pustular Psoriasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Generalized Pustular Psoriasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Generalized Pustular Psoriasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Generalized Pustular Psoriasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Generalized Pustular Psoriasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Generalized Pustular Psoriasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Generalized Pustular Psoriasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Generalized Pustular Psoriasis - Access and Reimbursement Overview
16 GENERALIZED PUSTULAR PSORIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GENERALIZED PUSTULAR PSORIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GENERALIZED PUSTULAR PSORIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
